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Experimental and epidemiological data suggest that vitamin D play a role in pathogenesis and 
progression of cancer, but prospective data on head and neck cancer (HNC) and oesophagus cancer 
are limited. The European Prospective Investigation into Cancer and Nutrition (EPIC) study recruited 
385,747 participants with blood samples between 1992 and 2000. This analysis includes 497 case-
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control pairs of the head and neck and oesophagus, as well as 443 additional controls. Circulating 
25(OH)D3 were measured in pre-diagnostic samples and evaluated in relation to HNC and oesophagus 
cancer risk and post-diagnosis all-cause mortality. After controlling for risk factors, a doubling of 25(OH)
D3 was associated with 30% lower odds of HNC (OR 0.70, 95% confidence interval [95% CI] 0.56–0.88, 
Ptrend = 0.001). Subsequent analyses by anatomical sub-site indicated clear inverse associations with 
risk of larynx and hypopharynx cancer combined (OR 0.55, 95CI% 0.39–0.78) and oral cavity cancer (OR 
0.60, 95CI% 0.42–0.87). Low 25(OH)D3 concentrations were also associated with higher risk of death 
from any cause among HNC cases. No clear association was seen with risk or survival for oesophageal 
cancer. Study participants with elevated circulating concentrations of 25(OH)D3 had decreased risk of 
HNC, as well as improved survival following diagnosis.
About 650,000 new cases of head and neck cancer (HNC) and 450,000 new cases of esophageal cancer occur 
worldwide each year1. This corresponds to approximately 11% of total cancer incidence. Global differences in 
incidence are primarily driven by its main risk factors tobacco and alcohol exposure2,3, but over the last decade 
infection by human papillomavirus has emerged as an important cause of HNC subsites, in particular oropharynx 
cancer4.
Vitamin D is a fat-soluble precursor to the steroid hormone calcitriol, primarily obtained via endogenous syn-
thesis in the skin after exposure to sunlight5,6, and is fundamental for absorption of dietary calcium and maintain-
ing bone health5,7. Vitamin D is also thought to have a protective role in cancer development and progression, and 
there is a large body of evidence from mechanistic studies supporting a role of vitamin D in multiple hallmarks 
of carcinogenesis7,8.
Vitamin D is metabolised in the liver to 25-hydroxyvitamin D [25(OH)D] and can be measured in the circu-
lation to assess an individual’s vitamin D status8. In contrast to mechanistic studies, epidemiological studies of 
circulating 25(OH)D have not provided consistent evidence supporting a beneficial role of vitamin D in terms 
of cancer incidence, the exception being colorectal cancer for which the majority of studies support an inverse 
association between circulating vitamin D and risk9,10. Circulating 25(OH)D has not been frequently studied in 
relation to cancers of the head and neck and esophagus, and the literature is to date limited and typically total 
based on measures of total vitamin D (25(OH)D). One small Danish study based on 44 HNC cases from three 
cohorts found a nominal inverse association between circulating 25(OH)D and HNC risk11. From larger studies 
of circulating 25(OH)D and HNC risk, there is evidence both of an inverse association with risk, and of no asso-
ciation. The Copenhagen City Heart Study (CCHS) based on 122 HNC cases reported a 45% increase hazards 
of HNC for a 50% reduction in circulating vitamin D12 whereas the Alpha-Tocopherol Beta Carotene (ATBC) 
study based on 340 HNC cases did not observe any clear association between circulating vitamin D and HNC 
risk13. Furthermore, the Vitamin D Pooling Project (VDPP) combining 8 prospective cohorts and based on 267 
esophageal cancer cases did not find any association with risk14. In addition, none of these studies have evaluated 
whether pre-diagnostic 25(OH)D is also related to risk of death after diagnosis.
While reverse causality is a principal concern in retrospective studies, the current study aimed to provide a 
comprehensive evaluation of pre-diagnostic circulating 25(OH)D and risk of cancers of the head and neck and 
oesophagus from a large case-control study nested within the European Prospective Investigation into Cancer 
and Nutrition (EPIC). In addition, we aimed to evaluate if pre-diagnostic circulating 25(OH)D is associated with 
survival following cancer diagnosis.
Results
Baseline characteristics. The final study population consisted of 497 cases, including 350 head and neck 
cancers and 147 oesophagus cancers, 497 individually matched controls and 443 subjects in control group 2. 
Approximately two thirds (68%) of the nested case-control population were men (Table 1), the median age at 
recruitment was 56.7 years (5th–95th percentile: 42–71) and the average time from blood draw to diagnosis for 
cases was 6.3 years. Control group 2 had similar demographic characteristics as the matched control group, but 
with a higher proportion of women.
Variations in circulating 25(OH)D3 by season and demographic characteristics. Predicted and 
observed concentrations in relation to season of blood draw are displayed in Fig. 1. Visual inspection suggests 
clear differences in circulating 25(OH)D3 that are consistent with sun exposure being the most important deter-
minant of circulating vitamin D, 25(OH)D3 concentrations were lowest among those who had their blood drawn 
around February and March and highest among those who had their blood drawn around August.
The relation of nutrient intake, lifestyle factors, smoking, and alcohol intake with plasma 25(OH)D3 are pre-
sented in Supplementary Table 1. In comparison with control participants who reported being never smokers, 
current smokers had 7% lower 25(OH)D3 concentrations on average (95% CI: − 14% to 0%), whereas former 
smokers had 9% higher 25(OH)D3 concentrations (95% CI: 2–16%). BMI was inversely associated with 25(OH)
D3 concentrations. No differences in 25(OH)D3 were seen in relation to alcohol intake.
Circulating 25(OH)D3 in relation to head and neck and esophagus cancer risk. The risk anal-
ysis results for overall HNC overall are shown in Table 2. Participants with higher 25(OH)D3 concentrations 
had lower HNC risk, with a doubling in plasma 25(OH)D3 being associated with 45% lower risk (conditional 
ORlog2 0.55, 95% CI 0.42–0.72, Ptrend 1 × 10−5; unconditional ORlog2 0.54, 95% CI 0.44–0.68, Ptrend 3 × 10−8). 
Following adjustments for education, alcohol consumption, circulating cotinine, tobacco exposure, and BMI, the 
unconditional OR estimates were slightly attenuated but remained indicative of an inverse association between 
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Discrete variables
No. (%) of Participants in Group
Cases (n = 497)
Matched controls 
(n = 497)
Control group 
n°2 (n = 443)
Participating countries
 France 5 (1%) 5 (1%) 13 (3%)
 Italy 63 (13%) 63 (13%) 88 (20%)
 Spain 91 (18%) 91 (18%) 52 (12%)
 United Kingdom 117 (24%) 117 (24%) 67 (15%)
 The Netherlands 70 (14%) 70 (14%) 46 (10%)
 Greece 20 (4%) 20 (4%) 17 (4%)
 Germany 96 (19%) 96 (19%) 124 (28%)
 Sweden 34 (7%) 34 (7%) 32 (7%)
 Norway 1 (0%) 1 (0%) 4 (1%)
Sex
 Men 340 (68%) 340 (68%) 234 (53%)
 Women 157 (32%) 157 (32%) 209 (47%)
Smoking status
 Never 103 (21%) 206 (41%) 206 (47%)
 Former 137 (28%) 177 (36%) 144 (33%)
  Years since quitting < 10 51(39) 46 (27) 40 (28)
  Years since quitting ≥ 10 80 (61) 125 (73) 102 (72)
 Current 249 (50%) 101 (20%) 90 (20%)
 Unknown 8 (2%) 13 (3%) 3 (1%)
Education
 Primary school or less 219 (44%) 192 (39%) 171 (39%)
 Technical/professional school 113 (23%) 132 (27%) 100 (23%)
 Secondary school 75 (15%) 61 (12%) 58 (13%)
 Higher education 68 (14%) 94 (19%) 100 (23%)
 Unknown 22 (4%) 18 (4%) 14 (3%)
Alcohol intake at recruitment (g/d)
  = 0 86 (17%) 58 (12%) 54 (12%)
 0.1–6 133 (27%) 162 (33%) 161 (36%)
 6.1–12 45 (9%) 74 (15%) 55 (12%)
 12.1–24 66 (13%) 88 (18%) 82 (19%)
 24.1–60 107 (22%) 90 (18%) 74 (17%)
 60.1–96 in men or > 60 in women 43 (9%) 18 (4%) 14 (3%)
 > 96 in men 15 (3%) 7 (1%) 3 (1%)
Body Mass Index (BMI)a
 < 25 195 (39%) 197 (40%) 179 (40%)
 25–29.9 221 (44%) 231 (46%) 187 (42%)
 ≥ 30 81 (16%) 69 (14%) 77 (17%)
Continuous variables, median (5th–95th percentile)
Age at blood draw (years) 56.8 (42–71) 56.7 (42–71) 56.7 (41–68)
Physical activity METs (hrs/week)b 72.0 (14–149) 72.3 (13–155) 79.2 (18–161)
Dietary variables
 Vitamin D (μ g/day) 3.2 (1.2–8.3) 3.2 (1.2–8.6) 3.2 (1.1–8.2)
 Calcium (mg/day) 890 (407–1848) 954 (465–1642) 946 (476–1653)
Serum concentrations variables
 25-hydroxyvitamin-D3, nmol/L 42.4 (14.4–79.1) 48.0 (19.2–80.2) 44.2 (20.8–79.7)
Clinical characteristics, case participants only
Age at diagnosis, median (range), years 62 (49–77)
Time from blood draw to diagnosis 6.3 (0.7–12.9)
Tumour site, No. (%)
 Esophagus
  Squamous cell carcinoma 73 (15%)
  Adenocarcinoma 74 15%)
Continued
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circulating 25(OH)D3 and risk (ORlog20.70, 95% CI 0.56–0.88, Ptrend 0.001). We also evaluated the association between 
concentrations of 25(OH)D3 and oesophageal cancer squamous cell carcinoma and adenocarcinoma, and whilst the 
Discrete variables
No. (%) of Participants in Group
Cases (n = 497)
Matched controls 
(n = 497)
Control group 
n°2 (n = 443)
 Head and Neckc
  Hypopharynx + Larynx 145 (29%)
  Gum + Oral cavity 110 (22%)
  Oropharynx 67 (13%)
  Head and neck otherc 28 (6%)
Table 1.  Baseline and Clinical Characteristics of Study Participants. aBMI is calculated as weight in 
kilograms divided by height in meters squared. bMetabolic equivalent intensity values (METs), defined as the 
ratio of the metabolic rate during an activity to a standard resting metabolic rate of 1.0 (4.184 kJ)·kg− 1·hour−1 
cAdenocarcinoma excluded.
Figure 1. Seasonal variation of 25(OH) D3 concentrations among all study participants. Scattered points 
show the measured values. The solid line represents the predicted geometric mean concentration given day 
of blood draw, which was modelled as a linear combination of sine and cosine functions. See the text of the 
methods section for further details.
No. of 
controls
Head 
and neck 
cancera 
(n = 350)
P for 
trendd
No. of 
controls
Esophagus 
Squamous 
Cell 
Carcinoma 
(n = 73)
P for 
trendd
No. of 
controls
Esophagus 
Adenocarcinoma 
(n = 74)
P for 
trendd
Minimally adjustedb
  Conditional 
matched control 350
0.55 
(0.42–0.72) 1 × 10
−5 73 0.78 (0.44–1.37) 0.39 74 0.86 (0.44–1.70) 0.66
  Unconditional 
all controls 
combined
940 0.54 (0.44–0.68) 3 × 10
−8 940 0.59 (0.38–0.91) 0.02 940 0.72 (0.44–1.18) 0.19
Fully adjustedc
  Conditional 
matched control 350
0.77 
(0.56–1.03) 0.07 73
0.83 
(0.36–1.94) 0.67 74 0.93 (0.39–2.23) 0.87
  Unconditional 
all controls 
combined
940 0.70 (0.56–0.88) 0.001 940
0.69 
(0.44–1.10) 0.11 940 0.74 (0.45–1.23) 0.26
Table 2.  Odds ratios for a doubling in concentration of 25-hydroxyvitamin D3 and the risk of cancers 
of the head and neck and the esophagus. aAdenocarcinoma excluded. bConditional adjusted models were 
assessed by conditional logistic regression, conditioning on matched case set. Unconditional adjusted models 
were assessed by unconditional logistic regression, adjusted for country, sex, age at recruitment (in 5 year 
groups) and seasonality. cFully adjusted models were further adjusted for educational attainment (in 5 groups), 
smoking status at baseline (never/former/current/missing), cotinine quartiles (based on the distribution among 
current smokers), alcohol intake at recruitment (g/day), and BMI (in 3 groups). dP for trend assessed by the base 
2 logarithm of the circulating levels.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:36017 | DOI: 10.1038/srep36017
OR estimates were consistent with that of overall HNC, the confidence intervals were wide (OR 0.69, 95% CI 0.44–1.10 
for esophageal squamous cell carcinoma [ESCC], and OR 0.74, 95% CI 0.45–1.23 for esopheageal adenocarci-
noma [EADC]). Because one of the key functions of vitamin D is to maintain calcium homoeostasis, we also 
included calcium intake in our models, but this did not affect the OR estimates (data not shown).
ORs of HNC across the observed range of 25(OH)D3 concentrations are depicted in Fig. 2. Compared to partic-
ipants having 25(OH)D3 blood concentrations of 50 nmol/L, odds of HNC were 42% higher for those with 25(OH)
D3 blood concentrations of 25 nmol/L, and 30% lower for those with 25(OH)D3 blood concentrations of 100 nmol/L.
Circulating 25(OH)D3 risk analysis stratified for head and neck cancer sub-sites demographic 
and lifestyle factors. Risk analyses stratified by HNC sub-sites are displayed in Table 3, and indicated that 
the association of 25(OH)D3 was particularly prominent for cancers of the larynx and hypopharynx (OR 0.55, 
95% CI 0.39–0.78) and for cancers of the oral cavity (OR 0.60, 95% CI 0.42–0.87). No association was observed 
with risk of oropharynx cancer (OR 0.92, 95% CI 0.58–1.45), although the sample size was small.
Figure 2. Odds ratio for head and neck cancer as a function of circulating concentrations of 25(OH) D3, 
relative to a concentration of 50 nmol/L. Log-base-2 25(OH) D3 was modelled as a continuous covariate. 
The left panel shows the minimally adjusted estimate, adjusted for age at recruitment (in 5 year groups), 
sex, country, and seasonality (sine and cosine functions of day of blood draw). The right panel depicts the 
association after additional adjustment for educational attainment (in 5 groups), smoking status (never/
former/current/missing), circulating cotinine (quartiles defined among the current smokers), alcohol intake at 
recruitment (g/day), and BMI (in 3 groups). Solid and dashed lines represent the maximum likelihood estimates 
and 95% confidence intervals respectively. The translucent lines are 1000 draws from the multivariate normal 
distribution defined by the maximum likelihood estimates and their variance covariance matrix, and thus give 
an indication of the posterior density for the odds ratio under a uniform prior on the regression coefficients. The 
“rug plot” under each panel shows the observed distribution of 25(OH) D3.
OR (95% CI)
No. of 
control
Larynx and 
Hypopharynx cases 
(n = 144)
Oral cavity 
and Gum cases 
(n = 108)
Oropharynx cases 
(n = 67)
Minimally adjusteda 940 0.42 (0.30–0.58) 0.47 (0.33–0.66) 0.79 (0.50–1.24)
 P for trendc 9 × 10−8 2 × 10−5 0.31
Fully adjustedb 940 0.55 (0.39–0.78) 0.60 (0.42–0.87) 0.92 (0.58–1.45)
 P for trendc 7 × 10−4 0.005 0.71
Table 3.  Odds ratios for a doubling in concentration of 25-hydroxyvitamin D3 and the risk of head and 
neck cancer by tumor sites. aAssessed by analysing cancer cases of the head and neck and all controls combined 
by unconditional logistic regression, adjusting for country, sex, age at recruitment (in 5 year groups) and 
seasonality. bFully adjusted models were further adjusted for educational attainment (in 5 groups), smoking 
status at baseline (never/former/current/missing), cotinine quartiles (based on the distribution among current 
smokers), alcohol intake at recruitment (g/day), and BMI (in 3 groups). cP for trend assessed by the base 2 
logarithm of the circulating levels.
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Stratifications by demographic and lifestyle factors (Supplementary Figure 1) showed that the association 
between circulating 25(OH)D3 and HNC risk was solely driven by former (unadjusted ORlog2 0.65, 95% CI 0.42–1.01) 
and current smokers (unadjusted ORlog2 0.47, 95% CI 0.34–0.66), and was not seen in never smokers (ORlog2 1.21, 
95% CI 0.72–2.03; (Pheterogeneity 0.02). In order to further evaluate if residual confounding by tobacco exposure 
might explain the association between circulating 25(OH)D3 and HNC risk in current smokers, we adjusted 
for circulating cotinine–a useful and objective indicator of recent tobacco exposure–which resulted in a small 
attenuation in OR estimates (cotinine adjusted ORlog2 0.55, 95% CI 0.39–0.80). Additional indicators of historical 
tobacco exposure, in particular duration and average number of cigarettes smoked per day (CPD), were incom-
plete and only available for 85% of the study population. Excluding subjects with missing data on these indicators 
yielded unadjusted OR estimates of 0.71 in former smokers (95% CI 0.44–1.14) and 0.46 (95% CI 0.31–0.66) in 
current smokers, with small attenuations in OR being observed when additionally adjusting for duration and 
CPD (former smokers ORlog2 0.77, 95% CI 0.45–1.24, current smoker ORlog2 0.55, 95% CI 0.36–0.81).
We also noted that the inverse association of circulating 25(OH)D3 with HNC risk was not affected after 
excluding cases within one year and 2 years after blood draw (ORlog2 0.69, 95% CI 0.54–0.88 and 0.69, 95% 
CI 0.54–0.89; respectively). Furthermore, the inverse association between circulating 25(OH)D3 and HNC risk 
was similar for cases diagnosed within three years after blood draw, as well as for those being diagnosed over 9 
years after their blood draw (P for heterogeneity 0.79). Some indications of differences in strength of association 
between circulating 25(OH)D3 and HNC risk were also seen when stratifying for groups of alcohol intake at 
recruitment, where no association was seen among subject with 0 grams of alcohol intake per day, although OR 
estimates in the other drinking categories were compatible with that overall.
All-cause mortality for study participants diagnosed with HNC and oesophagus cancer. In 
total, 145 deaths occurred among the HNC cases during the follow-up. Median time between diagnosis and 
death for those cases who died during follow-up was 15 months (range: 0 months to 12 years), and median time 
between blood collection and death was 8.5 years (range: 7 months to 15 years).
Results of Cox proportional hazards regression for 25(OH)D3 of all-cause mortality are shown in Fig. 3A. 
Similarly to the analysis of incidence, an overall inverse association between pre-diagnostic circulating 25(OH)
D3 and survival post HNC was observed; the HR for log2 25(OH)D3 [HRlog2] being 0.73 (95% CI 0.55–0.97). 
The hazard of death was 1.72 times higher (95% CI: 1.11–2.51) for participants with circulating concentrations 
of 25 nmol/L compared to those with 50 nmol/L. However, no further survival benefits were seen for cases with 
25(OH)D3 concentrations above 50 nmol/L, and there was even an indication that higher 25(OH)D3 concentra-
tions might be associated with elevated hazard of death, although very few participants had 25(OH)D3 greater 
than 75 nmol/L. For those deceased with HNC specifically indicated as underlying cause of death (87 deaths), 
HRlog2 was 0.68 (95% CI 0.51–0.91) and adjusting the cause-specific mortality analysis for potential confounders 
did not affect the HR estimates notably (HRlog2 0.71, 95% CI 0.53–0.96, Ptrend = 0.02). For comparison, 58 deaths 
occurred with other-than-HNC indicated as cause of death, and no association between circulating 25(OH)D3 
and survival was observed, the HRlog2 being 0.88 (95% CI = 0.53–1.26, Ptrend = 0.29).
Model-based estimates of the survival function evaluated at 25, 50, and 75 nmol/L of 25(OH)D3 among HNC 
cases are presented Fig. 3B. The expected 5-year post diagnostic survival probabilities for cases with 25(OH)D3 
concentrations of 25 nmol/L were 0.58 (95% CI 0.49, 0.65), and 0.71 (95% CI 0.64, 0.77) for those having 25(OH)
D3 concentrations of 50 nmol/L. Estimated HRs did not vary notably when stratifying by sex, age, country, edu-
cation, alcohol or tobacco exposure (Supplementary Figure 2). Of note, when stratifying the survival analysis by 
time from blood draw to diagnosis, the association of circulating 25(OH)D3 with all-cause mortality was apparent 
both among HNC cases diagnosed before 5 years (HRlog2 0.72, 95% CI 0.54–0.95) and those diagnosed over 5 
years after blood draw (HRlog2 0.80, 95% CI 0.62–1.03). Regarding the 91 death that occurred among esophageal 
cancer, circulating concentrations of 25(OH)D3 did not display any clear association with all-cause mortality, nor 
with esophageal-specific cause mortality.
We had limited information on disease stage, and adjusting for stage in an analysis restricted to those 161 
HNC cases (46%) for whom stage was available appeared to completely attenuate the association of circulating 
25(OH)D3 with all-cause mortality (HRlog2 = 0.96 95% CI = 0.76–1.20, Ptrend = 0.64), suggesting that the inverse 
association with all-cause mortality noted in the unadjusted survival analysis was completely mediated by differ-
ence in disease stage.
Discussion
To date, this is the largest prospective study investigating the relation between circulating vitamin D and head and 
neck cancer risk, and the first to also evaluate the relation with post-diagnosis survival. We report a notable risk 
decrease for participants with higher plasma vitamin D concentrations, as well as improved survival among cases 
having adequate pre-diagnostic vitamin D concentrations.
Vitamin D in cancer development and progression. The importance of vitamin D in maintaining 
bone health has long been recognized, and there is also an abundance of mechanistic studies supporting a bene-
ficial role of vitamin D in carcinogenesis by inhibiting tumour initiation and progression. Specifically, circulating 
vitamin D (measured as 25(OH)D3 in the current study) is a precursor to its active hydroxylated form calcitriol 
(1,25(OH)D3). Calcitriol is a potent steroid hormone that has been implicated by in vitro and in vivo models as 
having a potential anti-cancer influence by affecting multiple cancer hallmarks, including reducing angiogenesis, 
metastasis, cell invasion, inflammation, and proliferation, as well as stimulating apoptosis7. Some studies have 
also demonstrated a beneficial role of calcitriol in tobacco-related cancers, including oral, lung and bladder can-
cer, where reductions in angiogenesis, metastasis, and cell-modulatory effects have been suggested7,8,15–20.
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Prospective studies of 25(OH)D3 and head and neck cancer. Circulating vitamin D has been widely 
studied in relation to risk of multiple cancers in prospective studies, with the most consistent evidence accu-
mulated to date being an inverse association of colorectal cancer9,10. The body of evidence on other cancers is 
Figure 3. Post head and neck cancer survival. Panel A: Hazard ratio from a Cox model for all-cause mortality 
post HNC diagnosis as a function of circulating concentration of 25(OH) D3, relative to a concentration of 
50 nmol/L. 25(OH) D3 was modelled using restricted cubic splines with knots at the 10th, 33rd, 67th, and 90th 
percentiles of its distribution. The model was adjusted for age at recruitment (in 5 year groups), sex, country, 
seasonality (sine and cosine functions of day of blood draw), educational attainment (in 5 groups), smoking 
status (never/former/current/missing), circulating cotinine (quartiles defined among the current smokers) 
alcohol intake at recruitment (g/day), and BMI (in 3 groups). Solid and dashed lines represent the maximum 
likelihood estimates and 95% confidence intervals respectively. The translucent lines are 1000 draws from the 
multivariate normal distribution defined by the maximum likelihood estimates and their variance covariance 
matrix, and thus give an indication of the posterior density for the hazard ratio under a uniform prior on the 
regression coefficients. The “rug plot” shows the observed distribution of 25(OH) D3. Panel B: Survival function 
post HNC diagnosis evaluated at given concentrations of 25(OH) D3, derived from a flexible parametric survival 
model. Restricted cubic splines with knots at the 0th, 33rd, 67th, and 100th percentiles of the distribution of 
uncensored survival times were used to model the baseline hazard. Like the Cox model used to derive panel A, 
25(OH) D3 was modelled using restricted cubic splines with knots at the 10th, 33rd, 67th, and 90th percentiles 
of its distribution.
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contradictory and does not support a similar consistent inverse association of vitamin D with other common or 
rare cancers7. Head and neck cancer has been rarely studied in relation to circulating vitamin D, with only three 
prospective studies published to date; the CCHS based on 122 cases12, the ATBC study based on 340 cases13, and 
an additional small Danish study based on 44 cases from three cohorts11. The ATBC study did not observe any 
association between 25(OH)D and head and neck cancer risk, nor did the smaller Danish study, although the 
latter was underpowered to detect any notable association with risk. This contrasts to the results of the CCHS 
study which was a classical cohort study that assessed baseline 25(OH)D for a complete cohort of 9,791 partici-
pants at baseline, and then followed them for up to 28 years for a wide range of incident cancers. The CCHS study 
conducted their analysis by estimating the relative risk associated with a 50% reduction in circulating vitamin D 
(OR1/2), and whilst no association was noted for non-smoking related cancers overall (OR1/2: 0.95), the CCHS 
study reported a clear inverse association between 25(OH)D and smoking related cancers and circulating vitamin 
D (OR1/2: 1.20), with a particularly strong association for HNC (OR1/2: 1.44). The result was almost identical to 
that of the current EPIC study were we observed an OR of 0.70 for a doubling in 25(OH)D3, corresponding to an 
OR1/2 of 1.45. The VDPP study, a consortium of 8 prospective cohorts including 143 ESCC and 100 EADC, did 
not observe any clear relation with circulating vitamin D, an observation similar to our results.
We note that in the current study, the inverse association between vitamin D and HNC risk was solely 
observed in former and current smokers. In accordance with results from the vitamin D pooling project21, we 
observed 8% lower circulating vitamin D concentrations in current smokers compared to never smokers, but con-
currently 8% higher circulating vitamin D in former smokers compare to never smokers (Supplementary Table 
1). Residual confounding by tobacco exposure is therefore an important concern when interpreting the results, 
in particular among current smokers. In smoking stratified analyses we adjusted for several indicators of tobacco 
exposure, included circulating cotinine. Given that the inverse associations with risk in former and current smok-
ers were largely unchanged after adjusting for these additional tobacco exposure indicators, residual confounding 
by tobacco exposure does not appear to explain the observed decreases in head and neck cancer risk among study 
participants with elevated circulating vitamin D.
Further, the observed association was very stable during the follow-up, and most notable for a follow-up 
time of 9 years after recruitment, suggesting that the findings are unlikely to be due to reverse causation 
(Supplementary Figure 1). Considering that we were able to carefully control for current tobacco exposure 
using circulating cotinine measures, as well as alcohol consumption, we therefore interpret these results to mean 
that the decrease in head and neck cancer risk observed with elevated circulating vitamin D cannot be readily 
explained by known risk factors.
Vitamin D and cancer progression. Head and neck cancer prognosis is generally poor with overall 5-year 
survival rates of 50% to 60%, an important reason being that a large fraction of cases are diagnosed at advanced 
disease stage22–24. It was therefore interesting to note that in our analysis of all-cause mortality, pre-diagnostic 
25(OH)D3 was inversely associated with survival among head and neck cancer cases following their diagno-
sis. In contrast to the association noted with HNC risk, for which a log-linear trend was observed across the 
whole range of observed 25(OH)D3 concentrations, the association with survival was only evident in the lower 
25(OH)D3 range. This manifested in 72% higher hazard of death for cases with 25(OH)D3 concentrations of 
25 nmol/L compared with those with 50 nmol/L, with corresponding 5-year survival probabilities of 58% and 
71%, respectively. Estimated HRs did not vary notably when stratifying by time from blood draw to diagnosis, 
suggesting that pre-clinical symptoms would not seem likely to explain the association with all-cause mortality. 
Furthermore, subsequent cause-specific survival indicated that the association of 25(OH)D3 was primarily driven 
by deaths caused by HNC, but not other causes of death. However, taking disease stage into account appeared 
to explain most of the survival association of vitamin D, indicating that any survival benefit of having adequate 
pre-diagnostic 25(OH)D levels for HNC cases is likely to be mediated through differences in disease stage at 
diagnosis. Furthermore, it would have been informative to attain blood samples at diagnosis to fully evaluate the 
importance of circulating vitamin D for HNC prognosis.
Advantages and limitations. Our study distinguished itself from most previous prospective studies on 
vitamin D in that we used a mass spectrometry-based platform (LC-MS/MS) to specifically assay 25(OH)D3, 
rather than the more commonly used enzyme-linked immunosorbent assay (ELISA) which measures 25(OH)
D2 and 25(OH)D3 combined. Because the vast majority of total circulating vitamin D is in the form of 25(OH)
D3, we would not expect this to explain any discrepant results with other studies, even though evaluating 25(OH)
D3 would seem preferable as it precedes the most active form of vitamin D, calcitriol (1,25(OH)D3)7. Another 
distinguishing factor of our analysis was that we controlled for seasonal variations in vitamin D using trigono-
metric functions (Fig. 1), rather than discontinuous seasonal models, such as discrete variables indicating the 
four seasons. Using trigonometric functions has an advantage in providing a smooth seasonal model with mini-
mum degrees of freedom, whilst providing a valid account of the inherent differences in vitamin D related to sun 
exposure. Still, given the prospective design of our study, we do not expect differential bias between cases and 
controls by season, and the most important distinguishing factors comparing ours and others studies on circulat-
ing vitamin D in relation to HNC risk are a) the large study population and b), the multicentre recruitment across 
multiple European countries which would make the results more generalizable to other populations.
The principal limitation of our study is that 25(OH)D3 was measured using a single blood sample drawn in 
adulthood and therefore it may be possible that a single measurement does not capture exposure to vitamin D 
in an etiologically relevant period. Furthermore, in risk analyses stratified by cancer site, as well as in analyses of 
oesophagus cancer subtypes, the resulting small sample size hampered the statistical power to provide accurate 
risk estimates of potential risk associations.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:36017 | DOI: 10.1038/srep36017
Conclusions
EPIC participants with adequate circulating concentrations of vitamin D had lower risk of head and neck cancer 
and improved survival following their diagnosis. Known risk factors could only partly explain these associations. 
Overall, our results are consistent with a beneficial role of vitamin D in head and neck cancer aetiology.
Materials and Methods
Study cohort. The study was conducted within the European Prospective Investigation into Cancer and 
nutrition (EPIC). EPIC recruitment procedures, collection of questionnaire data, anthropometric measure-
ments, and blood samples have been described in detail elsewhere25. In brief, 521,330 individuals were recruited 
between 1992 and 2000 by 23 centres across 10 European countries, of which 385,747 contributed a blood sample. 
Blood fractions were aliquoted into 0.5 mL straws, which were heat-sealed and stored in liquid nitrogen tanks at 
− 196 °C, except at the Umeå centre in Sweden where samples were stored in 1.8 mL plastic tubes in − 80 °C freez-
ers. Participants completed self-administered questionnaires on lifestyle factors and diet.
Follow-up for Cancer Incidence. Incident cancer cases were identified at regular intervals through 
population-based cancer registries (Denmark, Italy except Naples, the Netherlands, Norway, Spain, Sweden and 
United Kingdom) or by active follow-up (France, Germany, Greece and Naples), which involved a combination of 
methods, including review of health insurance records, cancer and pathology registries, as well as direct contact 
with participants and their next-of-kin.
Mortality data, including vital status, cause and date of death, were obtained from mortality registries 
at the regional or national level. Subjects were followed up from study entry until cancer diagnosis (except 
non-melanoma skin cancer), death, emigration, or the end of the follow-up period for the relevant study cen-
tre. End of follow-up was defined as the latest date of complete follow-up for both cancer incidence and vital 
status and varied between study centres from December 2004 to June 2010. Vital status at follow-up is over 98% 
complete.
Selection of Case and Control Participants. We initially identified 1,273 subjects diagnosed with inci-
dent head and neck or oesophagus cancer within the entire EPIC cohort by the end of the follow-up period for all 
centres. These cancer cases were defined on the basis of the International Classification of Diseases for Oncology, 
Second Edition (ICD-O-2), and included: oral cavity (ICD C02.0-C02.9, C04.0-C04.9, C03.0-C03.9, C05.0-C06.9, 
C14.0-C14.9), oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), larynx (C32.0-C32.9), and 
oesophagus (C15.0-C15.9). Cases who did not donate a blood sample (n = 152), did not have enough plasma 
available for biochemical analysis (n = 20), had a history of another cancer (n = 158, except non melanoma skin 
cancer), were not histologically confirmed, or did not have questionnaire information available (n = 22), were 
excluded, leaving 921 eligible cases. Because the aetiology of squamous cell carcinoma (SCC) and adenocarci-
noma are thought to differ and the vast majority of HNC are SCC, we focused our analysis on SCC by excluding 
adenocarcinoma of the head and neck (n = 16). Also, we excluded esopheageal cases that were not classified as 
SCC or adenocarcinoma (n = 19). After further excluding cases from Denmark (n = 288) and the Malmö centre 
in Sweden (n = 101) who did not participate in this study, 497 eligible case participants with plasma samples were 
available for biochemical analyses. Data on histology were collected from each centre where possible.
For each case participant, one control was randomly chosen from appropriate risk sets consisting of all cohort 
members alive and free of cancer (except non-melanoma skin cancer) at the time (and hence age) of diagnosis of 
the index case. Matching criteria were country, sex, date of blood collection (± 1 month, which was relaxed to ± 5 
months for 22% of sets without available controls), and date of birth (± 1 year, which was relaxed to ± 5 years for 
1% of sets without available controls). In addition, we included 443 additional controls (control group 2) that were 
analysed in the context of a parallel study and individually matched to cases of another cancer site using identical 
matching criteria26.
The final dataset included 497 cancer cases and 497 individually matched controls, as well as 443 additional 
unmatched controls from control group 2 that contributed to unconditional and stratified risk analyses.
This research was conducted according to the principles expressed in the Declaration of Helsinki. This study 
was approved by the ethics review boards of the International Agency for Research on Cancer and individual 
EPIC centres. Informed consent was obtained from all EPIC participants at recruitment for use of their blood 
samples and data in future research.
Biochemical Analyses. All biochemical analyses were performed at Bevital A/S (http://www.bevital.no), 
Bergen, Norway. Liquid chromatography coupled to tandem mass spectrometry was used to measure plasma 
concentrations of 25-hydroxyvitamin D2 [25(OH)D2] and 25-hydroxyvitamin D3 [25(OH)D3]27, as well as coti-
nine27 (as indicator of recent nicotine exposure). We found that 25(OH)D2 was undetectable in the majority of the 
samples, thus our analyses focus on 25(OH)D3. We performed sensitivity analyses by using the sum of 25(OH)D3 
and 25(OH)D2 (setting undetectable levels of 25(OH)D2 to 0) and we observed similar results.
Samples were analysed in batches of 86 and quality control included 6 calibration samples, 2 control sam-
ples, and 1 blank sample in each batch. The limit of detection for 25(OH)D3 was 6.3 nmol/L, and within- and 
between-day coefficients of variation were 4.4 to 8.2%. All plasma samples were kept at − 80 °C and all HNC and 
oesophagus cancer cases and their individual matched controls were analysed together within the same batches 
in random order. Samples from control group 2 were evenly and randomly interspersed across the batches to 
ensure that no differential differences in 25(OH)D concentrations occurred. The laboratory staff was blinded to 
the case-control status of the blood samples.
Statistical Analyses. We initially used conditional logistic regression, conditioning on matched case-sets, 
to evaluate the relation between circulating 25(OH)D3 and disease risk. Odds ratios (OR) and 95% confidence 
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interval (CI) were calculated for the base 2 logarithm (log2) of 25(OH)D3 as estimates of the relative risk asso-
ciated with a doubling in 25(OH)D3 concentrations. In order to increase the statistical power, we incorporated 
control group 2 in the risk analysis by use of unconditional logistic regression, adjusting for age at recruitment 
in years, sex and country of recruitment, as well as seasonality in 25(OH)D3 concentrations by fitting two pairs 
of sine and cosine functions of the day of blood draw (scaled to be between 0 and 1 through out any year). This 
method efficiently accounts for seasonal effects by providing smooth predictions without artificial discontinui-
ties throughout the year. The logistic regression estimates were nearly identical with and without control group 
2, and we therefore focused the result presentation of the risk analysis on the unconditional analyses with the 
matched controls and control group 2 combined. Additional adjustments were performed to account for possible 
confounding by known risk factors, including tobacco exposure (smoking status [never, former, current], and 
for cotinine concentrations [defined using quantiles of the distribution among current smokers]), alcohol con-
sumption (self-reported intake in grams per day at recruitment [g/day]), as well as educational attainment (in five 
categories). Including additional smoking variables (duration of smoking, average cigarettes smoked per day) and 
body mass index did not alter the results notably and were not included in the final models. In order to the assess 
the statistical significance, log-linear trends (Ptrend) were calculated by including the base 2 logarithm (log2) of the 
biomarker concentration as a continuous variable in separate logistic regression models.
The relation between circulating pre-diagnostic 25(OH)D3 and post-diagnostic survival was assessed by calcu-
lating hazard ratios (HR) of all-cause mortality among incident head and neck and oesophagus cancer cases using 
a Cox proportional hazards model with time since diagnosis as the time-scale. We modelled 25(OH)D3 using 
restricted cubic splines with knots at its 10th, 33rd, 67th, and 90th percentiles, adjusting for the same covariates as 
in the unconditional logistic regression models, as well as age at diagnosis (years). Visual inspection of smoothed 
scaled Schoenfeld residuals revealed no notable departure from proportional hazards. In order to estimate the 
survival function at given concentrations of 25(OH)D3, we fitted a flexible parametric survival model28, modelling 
the baseline cumulative hazard with restricted cubic splines (knots at the 0th, 33rd, 67th, and 100th percentiles of 
the distribution of failure times).
The statistical uncertainty was evaluated by sampling from the asymptotic distribution of the regression coef-
ficients (the multivariate normal distribution with location and scale given by the maximum likelihood estimates 
and their variance-covariance matrix respectively). 1000 samples were drawn for each model and used to generate 
plausible predicted OR and HR. We plotted predictions that fall within the 95% CI to provide a visual impres-
sion of the 95% highest posterior density for the estimates under uniform prior distributions. All P-values were 
two-sided and statistical analyses were conducted using SAS version 9.2 (Cary, NC) and R version 3.0.229.
Ethical approval. This study was approved by the ethics review boards of the International Agency for 
Research on Cancer and individual EPIC centres. All EPIC participants provided written consent at recruitment 
for use of their blood samples and data in future research.
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